Thomas Hill
CorpComms@us.sumitomo-pharma.com
News Releases
Stay up to date with SMPA
The latest company news, press releases, and resources about Sumitomo Pharma America, our employees, our partners, and our latest innovations.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 22, 2022
Enzyvant, a commercial-stage biotechnology company with a focus on regenerative medicines for rare diseases, announced today plans to develop a Good Manufacturing Practice (GMP)-compliant...
-
Feb 9, 2022
MARLBOROUGH, Mass. & PRINCETON, N.J., February 09, 2022 08:00 am (BUSINESS WIRE) — Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc....
-
Oct 8, 2021•RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia
CAMBRIDGE, Mass. & BASEL, Switzerland, October 8, 2021 (GLOBE NEWSWIRE) – Enzyvant today announced the U.S. Food and Drug Administration (FDA) approval of RETHYMIC® (allogeneic processed thymus...
-
Sep 30, 2021-Companies to advance four promising Sunovion compounds for people living with serious neuropsychiatric conditions-
MARLBOROUGH, Mass. & OSAKA, Japan & TOKYO, Japan--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and...
-
Jun 29, 2021•Co-promotion extends sales and market access efforts to reach primary care physicians who treat OAB patients
IRVINE, Calif. & BASEL, Switzerland & MARLBOROUGH, Mass., June 29, 2021 at 9:00 AM EDT (BUSINESS WIRE)– Urovant Sciences, Inc. and Sunovion Pharmaceuticals Inc. today announced the launch of...